"The voice for cancer physicians and their patients in Massachusetts."

FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)

03 Feb 2022 7:00 AM | Katy Monaco (Administrator)

The U.S. Food and Drug Administration (FDA) is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib) approved to treat two specific types of lymphomas, which are cancers that affect the body’s immune system. Read More.

Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org

Powered by Wild Apricot Membership Software